166 related articles for article (PubMed ID: 34303003)
1. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
[TBL] [Abstract][Full Text] [Related]
2. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
3. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
6. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
Wei L; Kao JH
Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
[TBL] [Abstract][Full Text] [Related]
7. Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis.
Yao Y; Zhang J; Li X; Zao X; Cao X; Chen G; Ye Y
Front Public Health; 2022; 10():1037527. PubMed ID: 36407996
[TBL] [Abstract][Full Text] [Related]
8. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
Liu ZH; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
12. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
Seo Y; Yano Y
World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
15. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B.
Lee SK; Kwon JH; Lee SW; Jang JW; Nam H; Baik KW; Yoo SH; Nam SW; Sung PS; Bae SH; Choi JY; Yoon SK
Liver Int; 2021 Feb; 41(2):288-294. PubMed ID: 33043567
[TBL] [Abstract][Full Text] [Related]
16. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
17. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients.
Zhang Q; Li G; Yu Y; Qiu C; Zheng J; Zhang H; Zhang M; Song Z; Yang Y; Du X; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Huang Y; Zhang J; Chen Z; Zhang W
J Viral Hepat; 2019 Jul; 26 Suppl 1():59-68. PubMed ID: 31380588
[TBL] [Abstract][Full Text] [Related]
18. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
Jiang S; Guo S; Huang Y; Xu J; Li Y; Zeng Y; Guo Y; Ouyang L; Zhu C; Zhao W; Zhang Q; Guo Q; Xin H; Xie Q
Antiviral Res; 2024 Jun; 226():105892. PubMed ID: 38663455
[TBL] [Abstract][Full Text] [Related]
19. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
20. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
